MiniPDX

MiniPDX represents a novel platform of fast turnaround (7 days) in vivo drug sensitivity test, using either fresh patient tumor samples or tissues from established PDX models. Using MiniPDX for ranking the drug/treatment approved in clinical practice facilitates prioritization of the best strategy for benefiting patient in order to achieve precision medicine, while screening a series of small/large molecules within the similar scaffold enables selection of the best candidate for further drug R&D. Importantly, performing MiniPDX Mouse Trial using fresh tumor samples generated from clinic is beneficial for determination of potential clinical indication that would be fit for the investigating new drug.

MiniPDX

MiniPDX - Learn about a new, faster PDX process

Register Today!


LIDE has completed over 2,400 MiniPDX assays for precision medicine in clinical, including over 50 indications.

MiniPDX assays for precision medicine

Download Overview

Winner 2021 AAALAC 3Rs Award

Winner 2021 AAALAC 3Rs Award